Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Autophagy Mechanism In Schizophrenia Revealed

This article was originally published in Start Up

Executive Summary

Most of the current industry interest in autophagy – a mechanism cells use to degrade and remove damaged material – is centered on its role as a cancer drug target, but autophagy is also a neuroprotective mechanism. Now, a research team has shown its involvement in schizophrenia, opening the door for new drug and diagnostic development efforts.

You may also be interested in...



Exploiting Autophagy to Kill Cancer Cells

Scientists at Stanford have identified a compound that kills most kidney cancer cells without disturbing normal tissue. A new weapon against renal cell carcinoma would be welcome enough. But this research and other recent findings are pointing to how the emerging understanding of autophagy, a natural regulatory process in cells, may be useful in the design of new therapies in cancer and also, potentially, neurodegenerative and immunologic diseases.

Pharma’s Digital Pathology Build-Out; Part 2 – What It Means

Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.

Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play

Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC092545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel